Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Genix Pharmaceuticals ( (TSE:GENX) ).
Genix Pharmaceuticals Corporation announced the results of its 2025 Annual General and Special Meeting of Shareholders, where over 67% of shares were represented. Shareholders elected five members to the Board of Directors, approved Buckley Dodds CPA as auditors, and passed a resolution for the company’s Stock Option Plan. This meeting underscores the shareholders’ support and the company’s commitment to its strategic goals, potentially strengthening its market position in the ophthalmic drug industry.
More about Genix Pharmaceuticals
Genix Pharmaceuticals Corporation is a Canadian company specializing in ophthalmic drugs. It focuses on the research, development, manufacture, licensing, and sales of innovative prescription and OTC ophthalmological products, targeting the needs of consumers worldwide, particularly aging baby boomers. The company has three products pending Health Canada approval.
Average Trading Volume: 28,342
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$2.07M
For a thorough assessment of GENX stock, go to TipRanks’ Stock Analysis page.